Your browser doesn't support javascript.
loading
Does pre-arthroplasty antiviral treatment for hepatitis C reduce complication rates after total shoulder arthroplasty? A matched cohort study.
Ross, Austin J; Ross, Bailey J; Lee, Olivia C; Williams, Garrett H; Savoie, Felix H; O'Brien, Michael J; Sanchez, Fernando L; Sherman, William F.
Affiliation
  • Ross AJ; Tulane University School of Medicine, Department of Orthopaedic Surgery, New Orleans, LA, USA.
  • Ross BJ; Emory University School of Medicine, Department of Orthopaedics, Atlanta, GA, USA.
  • Lee OC; Tulane University School of Medicine, Department of Orthopaedic Surgery, New Orleans, LA, USA.
  • Williams GH; Louisiana State University School of Medicine, Department of Orthopaedic Surgery & Southeast Louisiana Veterans Health Care System, New Orleans, LA, USA.
  • Savoie FH; Tulane University School of Medicine, Department of Orthopaedic Surgery, New Orleans, LA, USA.
  • O'Brien MJ; Tulane University School of Medicine, Department of Orthopaedic Surgery, New Orleans, LA, USA.
  • Sanchez FL; Tulane University School of Medicine, Department of Orthopaedic Surgery, New Orleans, LA, USA.
  • Sherman WF; Tulane University School of Medicine, Department of Orthopaedic Surgery, New Orleans, LA, USA.
JSES Int ; 6(6): 910-916, 2022 Nov.
Article in En | MEDLINE | ID: mdl-36353415
ABSTRACT

Background:

Hepatitis C virus (HCV) is associated with increased complications of risk after arthroplasty. The purpose of this study was to examine the impact of HCV and a pre-arthroplasty antiviral treatment on complications following total shoulder arthroplasty (TSA).

Methods:

A retrospective matched cohort study was conducted using an administrative claims database. Patients who underwent TSA were identified with Current Procedural Terminology -23472 and International Classification of Diseases procedural codes. A total of 1244 HCV patients were matched 13 with 3732 noninfected controls across age, sex, diabetes mellitus, tobacco use, and obesity. The HCV patients with treatment before TSA were identified by claims containing antiviral drug codes. Multivariable logistic regression was used to compare rates of 90-day medical complications and prosthesis-related complications within 2 years postoperatively for (1) HCV patients vs. controls, (2) antiviral-treated HCV patients vs. controls, and (3) antiviral-treated HCV patients vs. untreated HCV patients.

Results:

Patients with HCV exhibited significantly higher rates of blood transfusion (OR 2.12), acute kidney injuries (OR 1.86), inpatient readmission (OR 2.06), revision TSA (OR 1.48), dislocation (OR 1.92), mechanical complications (OR 1.39), and prosthetic joint infection (OR 1.53) compared to controls. Antiviral-treated HCV patients exhibited a significantly lower rate of myocardial infarction (OR 0.27) and comparable rates of all other complications relative to controls (all P > .05). Compared to untreated HCV patients, antiviral-treated HCV patients exhibited significantly lower rates of 90-day medical complications (OR 0.57) and prosthetic joint infection (OR 0.36).

Conclusions:

HCV is associated with significantly increased complication rates after TSA. Antiviral treatment before TSA may reduce the risk of postoperative complications.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Etiology_studies / Observational_studies / Risk_factors_studies Language: En Journal: JSES Int Year: 2022 Document type: Article Affiliation country: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Etiology_studies / Observational_studies / Risk_factors_studies Language: En Journal: JSES Int Year: 2022 Document type: Article Affiliation country: United States